Therefore, further investigation of therapeutic strategies by co-targeting reciprocal interactions of AR and IGF1 pathways between epithelial tumor cells and surrounding tumor niches may improve clinical outcomes for advanced prostate cancer. This evidence concerns the gene IGF1 and prostate cancer.